뒤로
Medicenna Therapeutics Corp(MDNAF) 가격
MDNAF 주가 차트
MDNAF 수입
Medicenna Therapeutics Corp
$0.68
-1.72%
$-0.01
오늘 기준:Jan 26, 12:40:56 GMT-5
최신 수익 결과: Q2 '26
보고됨: 2025-11-11
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
MDNAF의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Medicenna Therapeutics Corp MDNAF의 지난 분기 매출 실적은 어땠나요?
Medicenna Therapeutics Corp의 매출 추정치는 얼마인가요?
Medicenna Therapeutics Corp의 수익 품질 점수는 얼마인가요?
Medicenna Therapeutics Corp는 언제 수익을 보고하나요?
Medicenna Therapeutics Corp의 예상 수익은 얼마인가요?
Medicenna Therapeutics Corp은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$0.7
시가
$0.7211
일일 범위
$0.6751 - $0.7211
52주 범위
$0.573 - $1.43
거래량
38.0K
평균 거래량
134.3K
EPS(TTM)
-0.12
배당수익률
--
시가총액
$57.3M
Medicenna Therapeutics Corp.란 무엇인가요?
Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. The company is headquartered in Toronto, Ontario and currently employs 18 full-time employees. The company went IPO on 2015-07-13. Its long-acting IL-2 Superkine, MDNA11, is a IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Its IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials, including a Phase IIb trial for recurrent glioblastoma (GBM). Its early-stage high-affinity IL-2B biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Its early-stage BiSKITs (Bifunctional SuperKine ImmunoTherapies) and the T-MASK (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.